Diplomat Announces Executive Promotions for Kaddis and Neill
FLINT, Mich. – Feb. 23, 2016 – The nation’s largest independent specialty pharmacy is promoting Atheer Kaddis and Lance Neill, in a move to position Diplomat for the next phase of growth.
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today two promotions within the company’s executive leadership team.
To learn more about our Diplomat executive team, click here.
Atheer Kaddis has been promoted to the Executive Vice President of Sales and Strategic Alignment. Kaddis leads the coordination of Diplomat’s strategies within the business units, giving him critical insights into operational efficiencies and areas of high growth potential. Lance Neill has been promoted to the Senior Vice President of Corporate Services. Neill is responsible for the strategic approaches and administration of Diplomat’s analytics, business intelligence, contract management, and now enterprise information security and compliance areas.
Prior to joining Diplomat in 2007, Kaddis served as director of pharmacy services clinical at Blue Cross Blue Shield of Michigan, where his responsibilities included formulary development, clinical program development, utilization management programs, specialty pharmacy programs and pay-for-performance programs. His other prior experience includes service as a staff pharmacist at William Beaumont Hospital, a clinical oncology specialist at Grace Hospital, a clinical program manager for the Ford Motor Company account at Blue Cross Blue Shield of Michigan and an associate director in clinical account management at Merck-Medco (now part of Express Scripts).
Prior to joining Diplomat, Neill served as director of commercial contracting and channel management at Wal-Mart Stores Inc., where he oversaw pharmacy contracting and network management for PBMs and large managed care organizations. He also held other management roles while at Wal-Mart, where he was responsible for pharmacy analytics, reporting, claims and audits. Prior to his work at Wal-Mart, Neill held a number of senior financial management positions within the health care and manufacturing industries. He also taught health care contracting as an adjunct professor at the University of Arkansas School of Law.
“Atheer and Lance have made significant contributions to Diplomat, each demonstrating a commitment to improving systems and processes and advancing programs that will allow us to lead Diplomat’s developmental efforts,” said Gary Kadlec, president of Diplomat. “They have each built strong, capable teams and helped play a pivotal role in executing Diplomat’s growth strategies. Their leadership and vision will help ensure Diplomat is able to achieve our goals and collaborate effectively among each of their teams.”
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | email@example.com
@PharmacDailyRT @PharmacDaily: @DiplomatRx to distribute Puma Biotechnology’s new cancer drug $DPLO https://t.co/gl0v6WURVV5 days ago
@DiplomatRxNerlynx (neratinib) tablets for HER2+ Breast Cancer in the Extended Adjuvant Setting https://t.co/vi3ACWhbfe5 days ago
@AJPB_JournalRT @AJPB_Journal: Be sure to check out our Insights page featuring videos of Cheryl Allen from @DiplomatRx discussing #RA https://t.co/qxZc…2 weeks ago
@DiplomatRxWe're with @340BCoalition this week in Washington D.C.! Come say hello.3 weeks ago
@SpecialtyPTimesRT @SpecialtyPTimes: Rheumatoid Arthritis Treatment Guidelines https://t.co/sEhe74UozC #rheumatoidarthritis @DiplomatRx3 weeks ago